MCPHS / Takeda - Patient Safety & Global Pharmacovigilance (2 yr), Post PharmD Fellow
MCPHS/Takeda
Application
Details
Posted: 10-Oct-24
Location: Cambridge, Massachusetts
Type: Fellowship
Job Setting:
Pharmaceutical Science/Industry
Specialty Practice Areas:
Medication Use Safety
Salary Details:
Fellows will receive a competitive stipend and benefit package, including comprehensive health insurance
Required Education:
PharmD
Additional Information:
Employer will assist with relocation costs.
Takeda Pharmaceuticals, in collaboration with MCPHS, offers unique fellowships to promote the role of the Doctor of Pharmacy (PharmD) within the biopharmaceutical industry. Fellows gain extensive experience through various practical activities in both industry and academic settings, which will enhance the potential for accelerated career development. The following options are offered by Takeda in conjunction with MCPHS:
Global Medical Information and Review, Oncology (1 year) - recruiting for 1 position
Global Scientific Communications, Oncology - recruiting for 1 position
Global Clinical Supply Chain - recruiting for 1 position
Patient Safety & Pharmacovigilance - recruiting for 1 position
Founded in 1781, Takeda is a patient-focused, values-based, research and development (R&D)-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future to people worldwide. Our passion and pursuit of potentially life-changing treatments for patients are deeply rooted in our distinguished 240-year history in Japan. At the U.S. headquarters for Takeda, four of our eight global business units and biologics manufacturing site are centered in Massachusetts enabling us to build relationships with cutting-edge companies, academic institutions, scientists and organizations who join us in the effort to discover, develop, and deliver new treatments to patients. We have 20 locations across the greater Boston area. As a R&D-driven organization, Takeda has state-of-the-art facilities to help advance the next generation of innovation. Takeda’s pharmaceutical products are marketed in around 100 countries worldwide, including partnerships (marketing alliance partners). The company has grown in size and scope both organically and through acquisition. Takeda-ism (our values of Integrity, Fairness, Honesty, and Perseverance) grounds us as we deliver on our role to serve the public by ensuring integrity in our every action for and on behalf of patients.
Takeda focuses its R&D efforts on four therapeutic areas: oncology, gastrointestinal and inflammation, rare diseases and neuroscience. We also make targeted R&D investments in plasma-derived therapies and vaccines. For more than 70 years, Takeda has supplied vaccines to protect the health of people in Japan. Today, Takeda’s global vaccine business is applying innovation to tackle some of the world’s most challenging infectious diseases, such as dengue, Zika and norovirus. We are developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline.
Eligibility
The MCPHS Biopharmaceutical Industry fellows will be selected on a nationally competitive basis. Applicants must have a Doctor of Pharmacy degree from an ACPE accredited college of pharmacy at the commencement of the program.
Candidates must have strong written and verbal communication skills and a strong interest in pursuing a career within the biopharmaceutical industry.
All candidates must have authorization to work in the United States throughout the duration of the one or two year fellowship. No visa sponsorship will be provided (i.e., TN, H-1B, STEM OPT, etc.).
Application Procedure
To be considered for an interview, please complete a fellowship application on the MCPHS SMApply application portal. Visit https://mcphs.smapply.io/
Please DO NOT request an interview within PPS. Our recruitment teams will contact qualified candidates via email to schedule interviews.
The MCPHS application portal (SMApply) will open up on Monday, October 7, 2024. Applicants must upload the following application materials to the online portal by Monday, November 4, 2024:
Letter of intent (addressed to the company specific program director/lead; found in each company brochure)
Curriculum vitae
Unofficial college transcript
Contact information for three references. References will receive an electronic recommendation form to complete separately.
Three recommendation evaluation forms must be submitted no later than November 20, 2024 via the online portal. This is NOT a letter of recommendation but an online form that the recommender will receive for completion from SMApply.
Application Review and Interview Timeline
Following a review of submitted applications, pre-screens and preliminary interviews will begin in October. Additional interviews, including final rounds will take place in December during ASHP. Candidates will be notified if selected for an interview. The process is rigorous and competitive; therefore candidates should submit their applications well in advance of posted deadlines as priority will be given to those who apply early.
ASHP Midyear and Onsite Interviews
The fellowship program will be conducting in-person interviews at the ASHP Midyear Clinical Meeting in New Orleans, LA. Attendance is strongly encouraged, but not required. Candidates attending in-person will not be able to interview without registering for both ASHP and PPS. Please refer to the ASHP & PPS website for registration details.
Top candidates may be invited for interviews at the sponsoring company’s location.
AIFA First Offer Date
The choice of a Post-Doctoral Fellowship is an important decision. MCPHS, in conjunction with the Alliance of Industry Fellowship Associates (AIFA), has aligned to extend offers for Fellowships no earlier than December 16, 2024. We believe this is a positive reflection of the cultures our Programs offer, and that culture is a critical consideration in choice of Fellowship. We hope that other academic and non-academic Fellowship Programs will NOT pressure candidates to accept offers prior to this aligned offer date.
We see this respect for candidate choice as a common aspect of each of our Program's cultures. We hope that other academic and non-academic Fellowship Programs will respect this timeline.
Founded in 1781, Takeda is a patient-focused, values-based, research and development (R&D)-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future to people worldwide. Our passion and pursuit of potentially life-changing treatments for patients are deeply rooted in our distinguished 240-year history in Japan. At the U.S. headquarters for Takeda, four of our eight global business units and biologics manufacturing site are centered in Massachusetts enabling us to build relationships with cutting-edge companies, academic institutions, scientists and organizations who join us in the effort to discover, develop, and deliver new treatments to patients. We have 20 locations across the greater Boston area. As a R&D-driven organization, Takeda has state-of-the-art facilities to help advance the next generation of innovation. Takeda’s pharmaceutical products are marketed in around 100 countries worldwide, including partnerships (marketing alliance partners). The company has grown in size and scope both organically and through acquisition. Takeda-ism (our values of Integrity, Fairness, Honesty, and Perseverance) grounds us as we deliver on our role to... serve the public by ensuring integrity in our every action for and on behalf of patients.
Takeda focuses its R&D efforts on four therapeutic areas: oncology, gastroenterology (GI), rare diseases and neuroscience. We also make targeted R&D investments in plasma-derived therapies and vaccines. For more than 70 years, Takeda has supplied vaccines to protect the health of people in Japan. Today, Takeda’s global vaccine business is applying innovation to tackle some of the world’s most challenging infectious diseases, such as dengue, Zika and norovirus. We are developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline.